Roth Capital Reiterates Buy on Coya Therapeutics, Maintains $12 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 89.9%

Neg 0% Neu 89.9% Pos 0%

Roth Capital analyst Boobalan Pachaiyappan reiterates Coya Therapeutics (NASDAQ:COYA) with a Buy and maintains $12 price target.